Dyne Therapeutics posts one-year Phase 1/2 ACHIEVE data for z-basivarsen in DM1

Dyne Therapeutics reported additional one-year Phase 1/2 ACHIEVE data for z-basivarsen in myotonic dystrophy type 1, with sustained improvements versus baseline, placebo and a matched natural history cohort, and said registrational expansion topline remains on track for Q1 2027.